Please login to the form below

Not currently logged in
Email:
Password:

Exelixis appoints Andrew Peters to newly created position

He joins the biotech as its vice president, strategy

ExelixisCalifornia, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy.

In this newly created role, Peters will work with the Exelixis leadership team to refine the company’s mid- and long-term strategy, which is focused on advancing the next generation of Exelixis medicines.

Commenting on his appointment, Michael Morrissey, president and chief executive officer of Exelixis, said: “Andrew’s extensive experience as a biotechnology industry analyst makes him a valuable addition to the Exelixis team as we work to identify potential future growth opportunities for the company.

“His familiarity with Exelixis and the biotech landscape should make for a seamless transition into his new role.”

Prior to his new role, Peters served as a director and senior analyst for Deutsche Bank Securities.

He has also held roles UBS Securities, Susquehanna International Group and Morgan Joseph & Co.

11th June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics